[Dimephosphone: results in atopic dermatitis]

To validate dimephosphone usage in combined therapy of patients with atopic dermatitis (AD), mental and behavioral disorders.

An immunological study covered 80 patients with AD aged 15 to 75 years. The patients were divided into two groups: 39 patients of group 1 received psychotropic drugs and conventional treatment. 41 patients of group 2 received the same treatment plus dimephosphon. The control group consisted of 30 healthy donors aged 15 to 45 years. Immune status was assessed before and after the treatment.

Immune status of untreated AD patients was characterized by high phagocytic activity of neutrophils, HBT-test parameters in spontaneous and stimulated reactions, leukocytes, neutrophils, TNF-alpha; low phagocytic number and index. After the treatment, in group I nonspecific resistance and TNF-alpha did not change. In group 2 these parameters normalized.

Adjuvant dimephosphone improves clinical course of AD, raises quality of AD patients' life. Positive effects of the drug are due to its ability to correct immune disorders in this pathology.